preclinical research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-25. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
According to historian Michael Worboys, malnutrition was essentially discovered, and the science of nutrition established, between World War I and World War II. Advances built on prior works like Casimir Funk's 1912 formulisation of the concept of vitamins. Scientific study of malnutrition increased in the 1920s and 1930s, and grew even more common after World War II. Non-governmental organizations and United Nations agencies began to devote considerable energy to alleviating malnutrition around the world. The exact methods and priorities for doing this tended to fluctuate over the years, with varying levels of focus on different types of malnutrition like Kwashiorkor or Marasmus; varying levels of concern on protein deficiency compared to vitamins, minerals and lack of raw calories; and varying priorities given to the problem of malnutrition in general compared to other health and development concerns. The green Revolution of the 1950s and 1960s saw considerable improvement in capability to prevent malnutrition. One of the first official global documents addressing Food security and global malnutrition was the 1948 Universal Declaration of Human Rights(UDHR). Within this document it stated that access to food was part of an adequate right to a standard of living. The Right to food was asserted in the International Covenant on Economic, Social and Cultural Rights, a treaty adopted by the United Nations General Assembly on December 16, 1966. The Right to food is a human right for people to feed themselves in dignity, be free from hunger, food insecurity, and malnutrition.
=== Penicillin binding proteins === Penicillin binding proteins (PBPs) catalyze steps in peptidoglycan metabolism. They carry out essential processes needed to build and modify the cell wall. These proteins are the targets blocked by penicillin and other beta-lactam antibiotics that bind to PBPs, hence their name. Some antibiotic-resistant isolates of H. Influenzae contain modified PBPs that resist beta-lactam action by producing beta-lactamases to degrade these antibiotics. This resistance is likely due to a N526K mutation, or R517H substitution in conjunction with another unknown mutation. The R517H substitution alone did not have a lower affinity for penicillin, and therefore cannot cause resistance alone. Beta-lactamase emergence in the 1970s caused the therapy for severe cases of H. influenzae to be changed from ampicillin to cephalosporins, however further resistance to cephalosporins has occurred due to changes in the transpeptidase domain of penicillin binding protein 3 (PBP3).
== History == Colistin was first isolated in Japan in 1949 by Y. Koyama, from a flask of fermenting Bacillus polymyxa var. colistinus, and became available for clinical use in 1959. Colistimethate sodium, a less toxic prodrug, became available for injection in 1959. In the 1980s, polymyxin use was widely discontinued because of nephro- and neurotoxicity. As multi-drug resistant bacteria became more prevalent in the 1990s, colistin started to get a second look as an emergency solution, in spite of toxicity. Colistin has also been used in agriculture, particularly in China from the 1980s onwards. Chinese production for agriculture exceeded 2700 tons in 2015. China banned colistin use for livestock growth promotion in 2016.
Sources: en.wikipedia.org
Sublingual administration of medications that are subject to a high first-pass effect with oral administration can result in improved bioavailability because the first pass through the intestines and liver is bypassed. As a result, sublingual estradiol has been found to result in estradiol levels and a ratio of estradiol to estrone that are substantially higher than oral estradiol. Maximal circulating levels of estradiol are as much as 10-fold higher with sublingual administration than with oral administration, and the absolute bioavailability of estradiol is approximately 5-fold higher. On the other hand, levels of estradiol fall rapidly with sublingual administration, whereas they remain elevated for a prolonged period of time with oral administration. This is due to the large circulating pool of hormonally inert estrogen conjugates with long half-lives that is reversibly generated with oral estradiol during first-pass metabolism, which serves as a metabolism-resistant and long-lasting reservoir for continuous reconversion back into estradiol. It is also responsible for the differences in ratios between sublingual estradiol and oral estradiol in terms of maximal estradiol levels (10:1) achieved and absolute bioavailability (5:1). A study in marmoset monkeys found that the bioavailability of sublingual estradiol was 10% of that of estradiol administered by intramuscular injection. After a dose of sublingual estradiol, levels of estrone start to slowly but progressively rise within 10 minutes.
On September 11, 2013, a large human chain united from north to south the territory of Catalonia in what was called the "Catalan Way towards Independence" and three months later the parties advocating the "consultation" agreed on the question and the date of the consultation, set for November 9, 2014. In January 2014, the parliament of Catalonia passed a motion requesting the Congress of Deputies to cede the competence to hold the referendum, but on April 8 the request was rejected by the plenary by an overwhelming majority. As for the political crisis, the coming to power of the People's Party did not improve citizens' perception of politics. In November 2012 the barometer of the CIS indicated that the percentage of people fairly or very satisfied with the functioning of democracy in Spain was less than 30% when ten years earlier, also governing the Popular Party – but in a period of strong economic growth – it was close to 60%. Likewise, many of the political institutions suffered a sharp fall in the valuation of public opinion such as political parties, the government, the Congress of Deputies, trade unions and business organizations, all of them below the score of 3 (on a scale of 0 to 10), according to the CIS barometer of 2013, and from which the monarchy was not spared valued with a 3.68.
Thin smears are similar to usual blood films and allow species identification, because the parasite's appearance is best preserved in this preparation. Thick smears allow the microscopist to screen a larger volume of blood and are about eleven times more sensitive than the thin film, so picking up low levels of infection is easier on the thick film, but the appearance of the parasite is much more distorted and therefore distinguishing between the different species can be much more difficult. From the thick smear, an experienced microscopist can detect all parasites they encounter. Microscopic diagnosis can be difficult because the early trophozoites ("ring form") of all four species look identical and it is never possible to diagnose species on the basis of a single ring form; species identification is always based on several trophozoites. The biggest pitfall in most laboratories in developed countries is leaving too great a delay between taking the blood sample and making the blood smears. As blood cools to room temperature, male gametocytes will divide and release microgametes: these are long sinuous filamentous structures that can be mistaken for organisms such as Borrelia. If the blood is kept at warmer temperatures, schizonts will rupture and merozoites invading erythrocytes will mistakenly give the appearance of the accolé form of P. falciparum. If P. vivax or P. ovale is left for several hours in EDTA, the buildup of acid in the sample will cause the parasitised erythrocytes to shrink and the parasite will roll up, simulating the appearance of P. malariae.
== Symptoms of poisoning == α-Amanitin has an unusually strong and specific attraction to the enzyme RNA polymerase II. Upon ingestion and uptake by liver cells, it binds to the RNA polymerase II enzyme, effectively causing cytolysis of hepatocytes (liver cells). Few effects are reported within 10 hours; it is not unusual for significant effects to take as long as 24 hours after ingestion to appear, with this delay in symptoms making α-amanitin poisoning even more difficult to diagnose and all the more dangerous. By then, it is far past the time in which stomach pumping would yield an efficient result. Diarrhea and cramps are the first symptoms, but those pass, giving a false sign of remission. Typically, on the 4th to 5th day, the toxin starts to have severe effects on the liver and kidneys, leading to total system failure in both. Death usually takes place around a week from ingestion. Around 15% of those poisoned will die within 10 days, progressing through a comatose stage to kidney failure, liver failure, hepatic coma, respiratory failure and death. Those who recover are at risk of permanent liver damage. Diagnosis is difficult, and is established by observation of the clinical symptoms as well as the presence of α-amanitin in the urine. Urine screening is generally most useful within 48 hours of ingestion.
Sources: en.wikipedia.org
=== As jewelry === Naturally occurring, beach-worn cone shell tops can function as beads without any further modification. In Hawaii, these natural beads were traditionally collected from the beach drift to make puka shell jewelry. Since it is difficult to obtain enough naturally occurring cone snail tops, almost all modern puka shell jewelry uses cheaper imitations, cut from thin shells of other species of mollusk, or made of plastic.
==== Brazil ==== On 26 April 2021, the Brazilian health regulator Anvisa rejected the use of Sputnik V, alleging a lack of consistent and reliable data and the presence of replicating adenovirus in the vaccine. RDIF and Sputnik V's official Twitter account said the decision may be politically motivated, pointing to a report by the United States government stating that the Office of Global Affairs persuaded Brazil to reject the vaccine. Several Brazilian states in the North and Northeast regions had already signed contracts for the acquisition of more than 30 million doses. Anvisa attributed its decision to a number of issues with the samples provided by Gamaleya for accreditation:
The first death row prisoner to be hanged in Singapore during the COVID-19 pandemic was 68-year-old Singaporean drug offender Abdul Kahar Othman on 30 March 2022, who had not appealed against his sentence and later executed as scheduled, therefore resuming executions in Singapore. By the time Abdul Kahar was executed, there were 62 prisoners on death row, awaiting execution (reduced to 61 with Nagaenthran's execution). Nagaenthran K. Dharmalingam was the second to be hanged on 27 April 2022 after Abdul Kahar. Datchinamurthy Kataiah was originally the third in line to be executed on 29 April 2022 after Nagaenthran before his execution was postponed due to an appeal. On 7 July 2022, Kalwant Singh Jogindar Singh and Norasharee Gous became the third and fourth convicts to be hanged in Singapore in 2022. In the same month, Nazeri Lajim was executed 15 days after Kalwant and Norasharee. Three more hangings - one on 26 July and two (Malaysian Rahmat Karimon and his accomplice Zainal Hamad) on 2 August - were conducted after Nazeri's execution. On 5 August 2022, 45-year-old Singaporean Abdul Rahim Shapiee and his 49-year-old accomplice Ong Seow Ping were the ninth and tenth to be executed. A 55-year-old Singaporean, whose name is unknown, was the eleventh to be executed for a drug charge on 7 October 2022. In total, eleven executions, all for drug trafficking, took place in the year 2022. In 2023, the first execution was carried out on 26 April 2023, when a 46-year-old Singaporean Tangaraju Suppiah, who was convicted in 2018 of marijuana trafficking, was hanged at dawn.
A cloud laboratory is a heavily automated, centralized research laboratory where scientists can run an experiment from a computer in a remote location. Cloud laboratories offer the execution of life science research experiments under a cloud computing service model, allowing researchers to retain full control over experimental design. Users create experimental protocols through a high-level API and the experiment is executed in the cloud laboratory, with no need for the user to be involved. Cloud labs reduce variability in experimental execution, as the code can be interrogated, analyzed, and executed repeatedly. They democratize access to expensive laboratory equipment while standardizing experimental execution, which could potentially help address the replication crisis—what might before have been described in a paper as "mix the samples" is replaced by instructions for a specified machine to mix at a specified rpm rate for a specified time, with relevant factors such as the ambient temperature logged. They also reduce costs by sharing capital costs across many users, by running experiments in parallel, and reducing instrument downtime. Finally, they facilitate collaboration by making it easier to share protocols, data, and data processing methods through the cloud.
== Addiction == Cocaine addiction results from complex molecular changes in the brain following multiple exposures to cocaine. Dynorphins have been shown to be an important part of this process. Although a single exposure to cocaine does not affect brain dynorphin levels, repeated exposures to the drug increases dynorphin concentrations in the striatum and substantia nigra in rats. One proposed molecular mechanism for increased dynorphin levels involves transcriptional regulation by CREB (3’, 5’-monophosphate response element binding protein). According to the model proposed by Carlezon et al., use of cocaine increases the expression of cAMP and cAMP-dependent protein kinase (PKA). PKA leads to the activation of CREB, which increases the expression of dynorphin in the nucleus accumbens and dorsal striatum, brain areas important in addiction. Dynorphin decreases dopamine release by binding to KORs on dopamine nerve terminals.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.